middle.news
Percheron puts funded path behind Vanderbilt AML trial
11:15am on Tuesday 20th of October, 2026 AEDT
•
Biotechnology
Read Story
Percheron puts funded path behind Vanderbilt AML trial
11:15am on Tuesday 20th of October, 2026 AEDT
Key Points
Vanderbilt trial start activities expected in 2026, with recruitment anticipated in the first half of 2027
$2.3 million institutional placement and $0.70 million R&D rebate strengthen funding
$4.875 million cash balance and reported 8.6-quarter funding runway
Dr Michael Baker formally commenced as CEO and managing director on 5 October
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Percheron Therapeutics (ASX:PER)
OPEN ARTICLE